ACURATE neo2 Transcatheter aortic valve implantation without balloon aortic valvuloplasty : direct ACURATE neo2
(2024) In International Journal of Cardiology 400.- Abstract
Background: ACURATE neo2 (Neo2) implantation is performed after systematic Balloon Aortic Valvuloplasty (BAV) in most patients. No reports exist about the feasibility and safety of direct Neo2 transcatheter aortic valve implantation (TAVI) in comparison to the standard practice. Aim: We aimed to identify the patients' baseline anatomical characteristics, procedural, and early post-procedural outcomes in patients treated using Neo2 with and without BAV. Methodology: This is a retrospective multicentre analysis of 499 patients with severe aortic stenosis who underwent TAVI using Neo2. The comparison was done according to the performance or omission of BAV. Echocardiography and computed tomography were analysed by an independent Core Lab.... (More)
Background: ACURATE neo2 (Neo2) implantation is performed after systematic Balloon Aortic Valvuloplasty (BAV) in most patients. No reports exist about the feasibility and safety of direct Neo2 transcatheter aortic valve implantation (TAVI) in comparison to the standard practice. Aim: We aimed to identify the patients' baseline anatomical characteristics, procedural, and early post-procedural outcomes in patients treated using Neo2 with and without BAV. Methodology: This is a retrospective multicentre analysis of 499 patients with severe aortic stenosis who underwent TAVI using Neo2. The comparison was done according to the performance or omission of BAV. Echocardiography and computed tomography were analysed by an independent Core Lab. Propensity score matching (PSM) was performed based on the annular diameter and AV calcium volume, which identified 84 matched pairs. Results: Among the cohort included, 391 (78%) patients received BAV (BAV-yes) and 108 (22%) were not attempted (BAV-no or Direct TAVI). Patients in BAV-no cohort had smaller annular diameter (22.6 vs 23.4 mm; p < 0.001) and lower calcium volume (163 vs 581 mm3; p < 0.001) compared to BAV-yes cohort. In the matched cohort, VARC-3 device technical success was similar (95%) and all other outcome measures were statistically comparable between cohorts. Conclusion: Direct TAVI using ACURATEneo2 without pre-TAVI balloon aortic valvuloplasty in patients with mild or less valve calcifications might be feasible and associated with comparable early outcomes compared to patients with similar anatomical features undergoing systematic balloon valvuloplasty.
(Less)
- author
- organization
- publishing date
- 2024-04-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- ACURATE neo2, Aortic valve calcification, Balloon aortic valvuloplasty, Self expandable valves, TAVI, Transcatheter aortic valve
- in
- International Journal of Cardiology
- volume
- 400
- article number
- 131792
- pages
- 10 pages
- publisher
- Elsevier
- external identifiers
-
- pmid:38244892
- scopus:85185175505
- ISSN
- 0167-5273
- DOI
- 10.1016/j.ijcard.2024.131792
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2024 The Authors
- id
- 452a9376-9821-43b6-b7ce-4486ecfd7c18
- date added to LUP
- 2024-02-29 12:28:05
- date last changed
- 2025-02-03 13:47:41
@article{452a9376-9821-43b6-b7ce-4486ecfd7c18,
abstract = {{<p>Background: ACURATE neo2 (Neo2) implantation is performed after systematic Balloon Aortic Valvuloplasty (BAV) in most patients. No reports exist about the feasibility and safety of direct Neo2 transcatheter aortic valve implantation (TAVI) in comparison to the standard practice. Aim: We aimed to identify the patients' baseline anatomical characteristics, procedural, and early post-procedural outcomes in patients treated using Neo2 with and without BAV. Methodology: This is a retrospective multicentre analysis of 499 patients with severe aortic stenosis who underwent TAVI using Neo2. The comparison was done according to the performance or omission of BAV. Echocardiography and computed tomography were analysed by an independent Core Lab. Propensity score matching (PSM) was performed based on the annular diameter and AV calcium volume, which identified 84 matched pairs. Results: Among the cohort included, 391 (78%) patients received BAV (BAV-yes) and 108 (22%) were not attempted (BAV-no or Direct TAVI). Patients in BAV-no cohort had smaller annular diameter (22.6 vs 23.4 mm; p < 0.001) and lower calcium volume (163 vs 581 mm<sup>3</sup>; p < 0.001) compared to BAV-yes cohort. In the matched cohort, VARC-3 device technical success was similar (95%) and all other outcome measures were statistically comparable between cohorts. Conclusion: Direct TAVI using ACURATEneo2 without pre-TAVI balloon aortic valvuloplasty in patients with mild or less valve calcifications might be feasible and associated with comparable early outcomes compared to patients with similar anatomical features undergoing systematic balloon valvuloplasty.</p>}},
author = {{Elkoumy, Ahmed and Rück, Andreas and Abdel-Wahab, Mohamed and Thiele, Holger and Rudolph, Tanja K. and Wolf, Alexander and Wambach, Jan Martin and De Backer, Ole and Sondergaard, Lars and Hengstenberg, Christian and Abdelshafy, Mahmoud and Arsang-Jang, Shahram and Elzomor, Hesham and Laine, Mika and Bjursten, Henrik and Götberg, Matthias and Wykrzykowska, Joanna J. and Mohamed, Sameh K. and Pellegrini, Costanza and Rheude, Tobias and Toggweiler, Stefan and Saleh, Nawzad and Meduri, Christopher U. and Kim, Won Keun and Soliman, Osama}},
issn = {{0167-5273}},
keywords = {{ACURATE neo2; Aortic valve calcification; Balloon aortic valvuloplasty; Self expandable valves; TAVI; Transcatheter aortic valve}},
language = {{eng}},
month = {{04}},
publisher = {{Elsevier}},
series = {{International Journal of Cardiology}},
title = {{ACURATE neo2 Transcatheter aortic valve implantation without balloon aortic valvuloplasty : direct ACURATE neo2}},
url = {{http://dx.doi.org/10.1016/j.ijcard.2024.131792}},
doi = {{10.1016/j.ijcard.2024.131792}},
volume = {{400}},
year = {{2024}},
}